Orexo continues to strengthen IP rights for ZUBSOLV®
Uppsala, Sweden – March 17, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued another patent relating to ZUBSOLV®, US Patent No. 10,946,010, which further strengthens the company’s intellectual property portfolio. ZUBSOLV® is Orexo’s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder.
The new patent expires in September 2032 and will be the seventh patent listed in the Orange Book relating to ZUBSOLV®.
Nikolaj Sørensen, President and CEO, said: “I am very pleased with the continued development of the patent portfolio protecting ZUBSOLV®. The strength of our patents ultimately allows us to focus on the important work of improving the quality of lives of patients with an unmet treatment need within the space of mental illness and substance use disorders. Strong patent protection is the backbone of our business and provides us with a solid foundation in our efforts to continue to develop innovative products for the benefit of patients and society.”
For further information, please contact:
Orexo AB (publ.)
|Nikolaj Sørensen, President and CEO||Lena Wange, IR & Communications Director|
|Tel: 018 780 88 00||Tel: +46 (0)18 780 88 00|
|Email: email@example.com||Email: firstname.lastname@example.org|
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine/naloxone products, where Orexo commercializes its lead product, ZUBSOLV®, for treatment of opioid use disorder. Total net sales for Orexo in 2020 amounted to SEK 664 million and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.
The information was submitted for publication at 8 am CET, on March 17, 2021.